Spotlight on MTX therapy in patients with RA – increasing vaccination response and combination therapy - European Medical Journal

Spotlight on MTX therapy in patients with RA – increasing vaccination response and combination therapy

The EMJ Podcast | Bonus Episode

The attendees can expect two highly interesting interviews with two well-known experts in the field of rheumatoid arthritis, namely Prof. Gerd Burmester and Prof. Mikkel Østergaard.

Prof. Burmester provides expert tips around MTX treatment of RA patients in the context of COVID-19 vaccinations and elaborates the effects of MTX hold on the vaccination response.

Prof. Østergaard elucidates the role of Methotrexate as an anchor drug in the treatment of rheumatoid arthritis, including the possibility of using it in a combination therapy. Furthermore, the advantages of subcutaneous Methotrexate over oral Methotrexate are highlighted.

Spotify | AppleAmazon MusicDownload MP3 (mp3, 09:54 mins)

 

This podcast has been funded by medac Gmbh, the market leader and innovator in scMTX therapy

Speaker Bio | Professor Mikkel Østergaard

Prof. Mikkel Ostergaard currently serves as the Head of the Copenhagen Center of Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics and University of Copenhagen, Denmark. He received both his MD and and PhD at the University of Copenhagen. His clinical work and research interests cover rheumatoid arthritis, psoriatic arthritis and spondyloarthritis, diagnostic and prognostic biomarkers in inflammatory joint diseases, clinical registries as well as imaging, particularly MRI and ultrasound. He was centrally involved in developing various MRI-based scoring methods, for example RAMRIS. Ostergaard has led or participated in numerous investigator-initiated clinical trials, and has presented and published his work extensively. Furthermore, he participates in international scientific workgroups and is editorial board member of a range of international journals. He was awarded several awards and holds honorary positions of various national and international rheumatological societies.

Speaker Bio | Gerd R. Burmester

Gerd R. Burmester, is Professor of Medicine and Rheumatology and a Senior Professor in the Department of Rheumatology and Clinical Immunology at the Charité – Universitätsmedizin Berlin, Freie Universität und Humboldt-Universität Berlin. Professor Burmester earned his medical degree from Hannover Medical School. Following his residency, he was awarded a postdoctoral fellowship at Rockefeller University, New York. Burmester is the recipient of numerous international awards, and he serves on several editorial boards, including the Journal of Rheumatology and Clinical Rheumatology, and he is the Associate Editor of Annals of the Rheumatic Diseases, official journal of EULAR. Being the author of more than 900 original and review articles, Burmester’s research interests include rheumatoid arthritis, Lyme borreliosis, immunotherapy, cellular activation mechanisms in inflammatory joint diseases, and tissue engineering. He served as President of the German Society of Rheumatology. He was a Member of the Executive Committee of the European League against Rheumatism, acting as Chairman of the Standing Committee on Investigative Rheumatology and became an honorary member of EULAR in 2006. He served as Treasurer of EULAR, and he was elected President Elect of EULAR in 2013. From 2015 – 2017 he was President of EULAR and served as Immediate Past President of EULAR until 2019. He became President of the Board of Trustees, FOREUM Foundation for Research in Rheumatology. Recently, he became Master of the American College of Rheumatology.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given